CTX-471 + KEYTRUDA® (pembrolizumab)

A Phase 1b arm enrolling patients who have metastatic or locally advanced non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer who have progressed after treatment with a checkpoint inhibitor. Patients enrolled in the study are treated with a combination of CTX-471 + KEYTRUDA® (pembrolizumab) with the goal of restoring response.